

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Joseph ROBERTS et al.
Title: GENETICALLY ENGINEERED
GLUTAMINASE AND ITS USE IN
ANTIVIRAL AND ANTICANCER
THERAPY
Appl. No.: Unassigned
Filing Date: 04/27/2001
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants submit herewith on Form PTO-1449 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 08/050,482, filed April 25, 1995. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

By



Date April 27, 2001

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 023032/0108		SERIAL NO. Unassigned	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Joseph ROBERTS et al.			
				FILING DATE 04/27/2001		GROUP ART UNIT Unassigned	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	4,762,707	08/88	JANSEN et al.			
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	A2	1 168 150	05/84	CANADA			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A3	MINTON et al., "Nucleotide Sequence Of The Erwinia Chrysanthemi NCPPB 1066 L-Asparaginase Gene", <i>Gene</i> , Vol. 46:25-35, (1986)					
	A4	KIM et al., "Asparaginase II Of Saccharomyces Cerevisiae", <i>J. Biol. Chem.</i> , Vol. 263:11948-11953, (1988)					
	A5	OVEJERA et al., "Efficacy Of 6-Diazo-5-oxo-L-Norleucine and N-[N-γ-Glutamyl-6-Diazo-5-oxo-Norleucinyl]-6- diazo-5-oxo-Norleucine Against Experimental Tumors In Conventional And Nude Mice", <i>Cancer Research</i> , Vol. 39:3220-3324, (1979)					
	A6	HOUCHENS, et al., "Therapy For Mouse Tumors And Human Tumor Xenografts With The Antitumor Antibiotic AT-125", <i>Cancer Treatment Reports</i> , Vol. 63:473-476, (1979)					
	A7	DUVALL, "6-Diazo-5-oxo-L-Norleucine", <i>Cancer Chemother. Reports</i> , Vol. 7:86-98, (1960)					
	A8	ROBERTS, "Purification And Properties Of A Highly Potent Antitumor Glutaminase-Asparaginase From <i>Pseudomonas 7A</i> ", <i>J. Biol. Chem.</i> , Vol. 251:2119-2123, (1976)					
	A9	HOLCENBERG et al., "Physical Properties Of Antitumor Glutaminase-Asparaginase From <i>Pseudomonas 7A</i> ", <i>J. Biol. Chem.</i> , Vol. 251:5375-5380, (1976)					
	A10	ROBERTS, et al., "Biologic And Antineoplastic Effects Of Enzyme-Mediated In Vivo Depletion Of L-Glutamine, L-Tryptophan, And L-Histidine", <i>Cancer Treatment Reports</i> , Vol. 63:1045-1054, (1979)					
	A11	ROBERTS, et al., Inhibition Of Mouse Retroviral Disease By Bioactive Glutaminase-Asparaginase", <i>J. Gen. Virol.</i> , Vol. 72:299-305, (1991)					
	A12	BONTHRON, "L-Asparaginase II Of Escherichia Coli K-12: Cloning, Mapping And Sequencing Of The ansB Gene", <i>Gene</i> , Vol. 91:101-105, (1990)					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

 1997 U.S. PTO
09/842628

04/27/01

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 023032/0108		SERIAL NO. Unassigned	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Joseph ROBERTS et al.			
				FILING DATE 04/27/2001		GROUP ART UNIT Unassigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A13	NICOLAU, et al., "Liposomes As Carriers For In Vivo Gene Transfer And Expression", <i>Meth. Enzymol.</i> , Vol. 149:157-176, (1987)					
	A14	HOLCENBERG et al., <i>Biochemistry</i> , Vol. 17(3):411-417, (1978)					
	A15	WU, et al., "Receptor-Mediated Gene Delivery In Vivo", <i>J. Biol. Chem.</i> , Vol. 266:14338-14342, (1991)					
	A16	SCHMER, et al., "Kinetics Of Uptake And Activity In Mouse Liver Of Glutaminase Coupled To Desialated Orosomucoid", <i>Biochimica et Biophysica Acta</i> , Vol. 538:397-405, (1978)					
	A17	OLLENSCHLAEGER, et al., "Intestinal Glutamine Metabolism Of Patients With HIV-Infection", <i>Clinical Nutrition</i> , Vol. 9:48-49, (1990)					
	A18	ROBERTS, et al., "Glutaminase Has Potent Antiretroviral Activity In Vivo", Abstract, <i>Proc. Am. Assoc. Cancer Res.</i> , Vol. 30:454, (1989)					
	A19	SHAPIRO, et al., "Isolation, Characterization, And In Vitro Expression Of A cDNA That Encodes The Kidney Isoenzyme Of The Mitochondrial Glutaminase", <i>J. Biol. Chem.</i> , Vol. 266:18792-18796, (1991)					
	A20	KATUNUMA, et al., "Organ Specific Control Of Glutamine Metabolism", <i>Adv. Enz. Reg.</i> , Vol. 5:55-69, (1967)					
	A21	GOLDSTEIN, "Relation Of Glutamate To Ammonia Productio nIn The Rat Kidney", <i>Am. J. Physiol.</i> , Vol. 210:661-666, (1966)					
	A22	CURTHOYS, et al., "The Distribution Of Glutaminase Isoenzymes In The Various Structures Of The nephron In Normal, Acidotic, And Alkalotic Rat Kidney", <i>J. Biol. Chem.</i> , Vol. 248:162-168, (1973)					
	A23	GOLDSTEIN, " Relation Of Glutamate To Ammonia Productio nIn The Rat Kidney", pp. 661-666					
	A24	SMITH, "Molecular Cloning Of A cDNA For Rat Hepatic Glutaminase, pp. 10631-10636, (1980)					
	A25	SMITH, "Rat Hepatic Glutaminase: Purification And Immunochemical Characterization", pp. 740-751, (1987)					
	A26	BANNER, "Isolation Of A cDNA For Rat Brain Glutaminase", pp. 247-254, (1988)					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							